No, it’s saying there is a limited part of the drug market where curing may not be as profitable as maintenance. So they’re trying to find alternate ways of financing that development. For most of pharma, curing is a payday.
That's the same as asking,
> "Is curing patients a sustainable business model?"
The offense in question is letting profits effect a decision to develop a treatment over a cure. You're literally spelling out the bad thing.
If the society says to manufacturer "if you do this, you'll get less money from us" that is effectively the society saying "please don't do this". People and governments vote with their wallets about what they want, and if they're "voting wrong" or ineffectively, then they need to change what they pay for, instead of being surprised that they don't get what they disincentivize.